About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Seminars in Oncology
›
Top Articles
Seminars in Oncology
Hematology
,
Oncology
5.5
(top 2%)
Impact Factor
6
(top 2%)
extended IF
148
(top 2%)
H-Index
901
authors
6.3K
papers
179.3K
citations
5.6K
citing journals
46.4K
citing authors
Most Cited Articles of Seminars in Oncology
Title
Year
Citations
Role of angiogenesis in tumor growth and metastasis
2002
1.9K
Phase I studies with bendamustine: an update
2002
1.2K
Molecular, biochemical, and cellular pharmacology of pemetrexed
2002
679
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
2003
677
Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications
2002
636
Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination
1995
633
Epidermal growth factor receptor targeting in cancer
2006
560
Overview of non-Hodgkin's lymphoma: biology, staging, and treatment
2003
489
Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society
1991
481
The anthracyclines: will we ever find a better doxorubicin?
1992
478
The National Cancer Institute: cancer drug discovery and development program
1992
473
Breast cancer before age 40 years
2009
471
Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality
2002
430
Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults
1980
429
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
1999
426
Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity
2004
420
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
2003
400
Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience
2001
398
An overview of HER2
2001
398
Cancer prevention with natural compounds
2010
350
The changing epidemiology of esophageal cancer
1999
346
Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy
2001
329
Factors influencing survival in high-grade gliomas
2003
326
Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the national surgical adjuvant breast and bowel project experience
2001
309
Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results
1998
299
0
1
2
next
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.